Yarrow Bioscience (YARW) Other Non Operating Income (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Other Non Operating Income came in at $231000.0 in Q1 2026, down 61.11% YoY from $594000.0 in Q1 2025, and down 82.23% on a QoQ basis from $1.3 million in Q2 2025.
Yarrow Bioscience (YARW) Other Non Operating Income (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Other Non Operating Income data on file, last reported at $231000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 61.11% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 million (down 12.28% YoY) and the FY2025 annual result came in at $3.0 million, down 21.31% from the prior year.
- Other Non Operating Income retreated to $231000.0 in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $1.3 million in Q2 2025 to a low of -$3000.0 in Q1 2022.
- A 5-year average of $513866.7 and a median of $280000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2023 — Other Non Operating Income soared 8866.67% — and 2026, when it plunged 61.11%.
- Tracing YARW's Other Non Operating Income over 5 years: stood at $236000.0 in 2022, then jumped by 188.14% to $680000.0 in 2023, then grew by 11.76% to $760000.0 in 2024, then surged by 71.05% to $1.3 million in 2025, then tumbled by 82.23% to $231000.0 in 2026.
- The last three Other Non Operating Income figures came in at $231000.0 (Q1 2026), $1.3 million (Q2 2025), and $594000.0 (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 203,000.00 |
| Mar 31, 2026 | 231,000.00 |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 594,000.00 |
| Dec 31, 2024 | 760,000.00 |
| Sep 30, 2024 | 934,000.00 |
| Jun 30, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.14 Mn |
| Dec 31, 2023 | 680,000.00 |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 280,000.00 |
| Mar 31, 2023 | 263,000.00 |
| Dec 31, 2022 | 236,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 52,000.00 |
| Mar 31, 2022 | -3,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | -35,000.00 |
| Jun 30, 2021 | -69,000.00 |
| Mar 31, 2021 | -57,000.00 |